Pharming Group N.V. announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial infarction at the University Hospital Basel, Switzerland.

Pharming Group announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S. Securities and Exchange Commission (SEC)

Pharming Group N.V. announces the publication of its Annual Report for the year ended 31 December 2020. In addition, the Company’s 2021 Annual General Meeting (AGM) will be held at 16:00CET on Wednesday, 19 May 2021. The Notice to Convene, Explanatory Notes, meeting documents and Form of Proxy can be found on the Company’s website, under Investors/Shareholders’ Meetings.

Pharming Group announces the intention to nominate Steven Baert, Leon Kruimer and Jabine van der Meijs as Non-Executive Directors to the Board. Their official appointments will be confirmed by the Company’s Annual General Meeting of Shareholders that will be held on 19 May 2021.

Pharming Group N.V. today announces that its Chief Executive Officer, Sijmen de Vries, will present at the 31st Annual Oppenheimer Healthcare Conference 2021 at 15:40-16:10 CET/10:40-11:10 EDT on 16 March 2021.

Pharming Group today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021

Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2020.

New program expected to improve access to genetic testing for activated PI3K delta syndrome (APDS), an ultra-rare immunodeficiency disease

Pharming’s CEO Sijmen de Vries and CFO Jeroen Wakkerman look back at 2020 and the recently published full year financial results.

Pharming Group announces that, effective today, its American Depositary Shares (“ADSs”) have been admitted for listing on the Nasdaq Global Market (“Nasdaq”) under the symbol “PHAR” and will begin trading tomorrow; Wednesday 23 December. Each ADS represents 10 of the Company’s ordinary shares of €0.01 nominal value (“Ordinary Shares”).